NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) has earned a consensus rating of “Moderate Buy” from the five ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $8.50.

Several equities analysts have recently issued reports on NRSN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroSense Therapeutics in a report on Friday, May 8th. Roth Mkm started coverage on NeuroSense Therapeutics in a report on Tuesday, March 10th. They issued a “buy” rating and a $3.00 price objective for the company. Finally, D. Boral Capital reissued a “buy” rating and issued a $14.00 price objective on shares of NeuroSense Therapeutics in a report on Wednesday, April 8th.

NeuroSense Therapeutics Stock Performance

NeuroSense Therapeutics stock opened at $0.71 on Thursday. The business’s 50-day simple moving average is $0.78 and its two-hundred day simple moving average is $0.86. The company has a market cap of $22.95 million, a PE ratio of -1.31 and a beta of 1.56. NeuroSense Therapeutics has a fifty-two week low of $0.63 and a fifty-two week high of $2.52.

Insider Activity

In related news, CEO Alon Ben-Noon acquired 250,000 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The stock was acquired at an average price of $0.80 per share, with a total value of $200,000.00. Following the acquisition, the chief executive officer directly owned 4,534,233 shares in the company, valued at $3,627,386.40. This represents a 5.84% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Or Eisenberg acquired 250,000 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The stock was bought at an average cost of $0.80 per share, with a total value of $200,000.00. Following the acquisition, the chief financial officer owned 1,504,050 shares in the company, valued at approximately $1,203,240. This trade represents a 19.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 27.40% of the company’s stock.

Hedge Funds Weigh In On NeuroSense Therapeutics

A number of large investors have recently bought and sold shares of the business. Yorkville Advisors Global LP acquired a new position in NeuroSense Therapeutics in the 4th quarter worth about $77,000. Squarepoint Ops LLC raised its holdings in NeuroSense Therapeutics by 91.0% in the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after purchasing an additional 45,450 shares during the period. Jane Street Group LLC acquired a new position in NeuroSense Therapeutics in the 2nd quarter worth about $54,000. Finally, Two Sigma Investments LP acquired a new position in NeuroSense Therapeutics in the 3rd quarter worth about $26,000. Institutional investors and hedge funds own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.